Read More

SomaLogic Expands Agreement With Novo Nordisk To 2025, Will Expand Its Use Of The SomaScan Proteomics Platform In Drug R&D Novo Nordisk Will Also Use SomaLogic’s SomaSignal Tests For Investigations Into Cardiometabolic And Other Diseases

SomaLogic, Inc., a leader in proteomics technology, announced today that it is extending its collaborative agreement with global healthcare innovator, Novo Nordisk. As part of the agreement, which now extends into the

NVO